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San-Huang-Xie-Xin-Tang (SHXT), composed of Coptidis rhizoma, Scutellariae radix,a n dRhei rhizoma, is a traditional Chinese
medicine used for complementary and alternative therapy of cardiovascular and neurodegenerative diseases via its anti-
inﬂammatory and antioxidative eﬀects. The aim of this study is to investigate the protective eﬀects of SHXT in the 1–methyl–4–
phenylpyridinium (MPP+)/1–methyl–4–phenyl–1,2,3,6–tetrahydropyridine (MPTP) models of Parkinson’s disease. Rat primary
mesencephalic neurons and mouse Parkinson disease model were used in this study. Oxidative stress was induced by MPP+ in vitro
and MPTP in vivo.I nM P P +-treated mesencephalic neuron cultures, SHXT signiﬁcantly increased the numbers of TH-positive
neurons. SHXT reduced apoptotic signals (cytochrome and caspase) and apoptotic death. MPP+-induced gp91phox activation and
ROS production were attenuated by SHXT. In addition, SHXT increased the levels of GSH and SOD in MPP+-treated neurons. In
MPTP animal model, SHXT markedly increased TH-positive neurons in the substantia nigra pars compacta (SNpc) and improved
motor activity of mice. In conclusion, the present results reveal the evidence that SHXT possesses beneﬁcial protection against
MPTP-induced neurotoxicity in this model of Parkinson’s disease via its antioxidative and antiapoptotic eﬀects. SHXT might be a
potentially alternative and complementary medicine for neuroprotection.
1.Introduction
San-Huang-Xie-Xin-Tang (SHXT) is a traditional Chinese
medicinal formula, containing Coptidis rhizoma (Coptis
chinesis Franch), Scutellariae radix (Scutellaria baicalensis
Georgi), and Rhei rhizoma (Rheum oﬃcinale Baill). SHXT
is traditionally used to treat various diseases via its anti-
inﬂammatory eﬀects. Some of the major components (e.g.,
baicalin, baicalein, wogonin, and emodin) in SHXT have
identiﬁed their potential protection on neuron. Baicalin
protects against cerebral ischemia/reperfusion in vivo and
oxygen-glucose deprivation in vitro [1, 2]. Baicalein prevents
6-OHDA-induced experimental parkinsonism [3], ischemia
injury [4], and traumatic brain injury [5]. Baicalein [6]
andwogonin[7]attenuateinﬂammation-mediatedneurode-
generation. Emodin, an anthraquinone derivative extracted
from Rhei rhizoma, decreased glutamate excitotoxicity [8]
and β-amyloid-induced neurotoxicity [9]. Accordingly,
SHXT is standardized and pharmacologically investigated in
our lab. We demonstrate that SHXT attenuates lipopolysac-
charide (LPS) and Helicobacter pylori-induced inﬂammatory
responses [10–12]. We also reveal the potential beneﬁts of
SHXT used in the treatment of pulmonary hypertension
[13]. We further prove the potential protective mechanisms
ofSHXTonactivatedmicroglia-and6-OHDA-inducedneu-
rotoxicity via its anti-inﬂammatory and antioxidative prop-
erties [14].
Oxidative stress has been implicated in the progression
and cellular damage in many neurodegenerative disorders,
such as Parkinson’s disease (PD), Alzheimer’s disease (AD),
and amyotrophic lateral sclerosis (ALS) [15]. PD is a
progressive neurodegenerative disease characterized by a loss
of dopaminergic neurons in substantia nigra pars compacta2 Evidence-Based Complementary and Alternative Medicine
(SNpc) and can be modeled by the neurotoxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) [16]. Oxidative
stress-induced mitochondrial dysfunction is recognized as a
key player in the pathogenesis of PD [17]. MPTP can cross
the blood-brain barrier and converts to its active metabolite
1-methyl-4-phenylpyridinium (MPP+)[ 18], which is selec-
tively accumulated by high-aﬃnity dopamine transporters
intothemitochondriaofdopaminergicneuronsandinduced
dopaminergic neuron death [19]. Since SHXT possesses
novel anti-inﬂammatory and antioxidative eﬀects, therefore,
we aimed to investigate the protective eﬀects and mecha-
nisms of SHXT on oxidative stress-induced neurotoxicity
by using MPP+ in vitro model and MPTP mouse model of
Parkinson’s disease.
2.MaterialsandMethods
2.1. Materials. The blended mixture of Coptidis rhizoma,
root of Scutellariae radix, and Rhei rhizoma was prepared
in a ratio of 1:1:2, respectively. The voucher specimen,
method for extraction and contents of each component in
SHXT were described in our previous study [11]. Brieﬂy, the
mixture was extracted with 5 parts distilled water for 1h,
centrifuged at 1500×g at room temperature to obtain the
supernatant and then concentrated under reduced pressure
at65◦CtoobtainthesemisolidformofSHXT(yield:23.2%),
which was made up by distilled water to contain 60%
water. The content (μg/mL) of each component in SHXT
analyzed by HPLC is as follows: baicalin 1153.07 ± 56.36,
baicalein 82.81±3.74, emodin 11.15±1.22, wogonin 19.55±
0.83, rhein 126.12 ± 3.84, berberine 62.14 ± 4.27, coptisine
6.15 ± 0.34, palmatine 25.11 ± 3.78, sennoside A 128.02 ±
13.56, and sennoside B 95.90 ± 3.59. Minimum essential
medium (MEM), fetal bovine serum (FBS), horse serum,
glutamine, B27, nonessential aminoacids, sodium pyruvate,
penicillin, amphotericin B, streptomycin, and Alexa Fluor
488 goat anti-rabbit IgG (H + L) were obtained from
Invitrogen (Carlsbad, CA, USA). All materials for SDS-
PAGE were obtained from Bio-Rad (Hercules, CA, USA).
Mouse antibodies against cytochrome c, rabbit antibody
against TH and caspase-3, and all horseradish peroxidase-
conjugated secondary antibodies were obtained from Santa
CruzBiotechnology(SantaCruz,CA,USA).Mouseantibody
against gp91phox was obtained from BD Bioscience (San
Jose, CA, USA). Mouse anticaspase-9 was obtained from
Millipore (Bedford, MA, USA). Enhanced chemilumines-
cence reagent and polyvinylidene diﬂuoride (PVDF) mem-
brane were purchased from PerkinElmer Life and Analytical
Sciences (Boston, MA, USA). LDH cytotoxicity assay kit
was purchased from G-Biosciences (St. Louis, MO, USA).
Annexin-V-FITC assay kit was obtained from Strong Biotech
Corporation (Taipei, Taiwan). Glutathione measurement kit
and superoxide dismutase activity kit were purchased from
Assay Designs (Ann Arbor, MI, USA). Simple stain mouse
MAX PO was purchased from Nichirei Biosciences (Tokyo,
Japan). Diaminobenzidine (DAB) kit was obtained from
BioGenex (San Ramon, CA, USA). All other materials were
purchased from Sigma Chemical Company (St. Louis, MO,
USA).
2.2. Animals. All animals used for this study were approved
by the Animal Care and Use Committee at the Kaohsiung
Medical University. Pregnant Sprague-Dawley rats and male
C57BL/6 mice (7-8 weeks old, 20–25g) were purchased
fromtheNationalLaboratoryAnimalBreedingandResearch
Center (Taipei, Taiwan). They were housed under conditions
of constant temperature and controlled illumination (lights
on between 7:30 and 19:30).
2.3. MPTP Mouse Model. Experimental Parkinson’s disease
model was established by intraperitoneal (i.p.) injection of
MPTP (20mg/kg four times at 2h interval). Mice received
SHXT (10mg/kg or 20mg/kg, i.p., once per day) for 7 days
while MPTP was given on the 8th day. Control animals
receivedsalineonly.Micehavetoundergolocomotoractivity
assay 7 days after MPTP treatment and sacriﬁced for TH
immunohistochemistry.
2.4. Primary Mesencephalic Neuron Cultures. Primary mes-
encephalic neuron cultures were prepared from gestation
day 15-16 rat embryos (E15-16). In brief, meninges-free
ventral mesencephalon were isolated and suspended. Cells
were plated onto 6-, 24-, or 96- well plates precoated
with 20μg/mL poly-L-lysine in MEM containing 10% FBS,
1 0 %h o r s es e r u m ,1 g / lg l u c o s e ,2 m ML - g l u t a m i n e ,1 m M
sodium pyruvate, 100μM nonessential aminoacids, 100
U/mL penicillin, 100μg/mL streptomycin, and 0.25μg/mL
amphotericin B at 37◦C in a humidiﬁed incubator under 5%
CO2 and 95% air. After 24h incubation, culture medium
was replaced by MEM supplemented with 2% B27 and
10μM cytosine arabinoside to control glia proliferation.
After further 48h, the medium was replaced with MEM
containing 2% B27 and the cells were allowed to develop in
vitro for 6 days.
2.5. MTT Assay. Cell viability was measured by a quantita-
tivecolorimetricassaywithMTT,showingthemitochondrial
activity of living cells. After indicated treatments, cells were
incubatedwith0.1mg/mLMTTfor3hat37◦C.Thereaction
was determined by addition of 100μLD M S O .T h ea m o u n t
of MTT formazan product was determined by measuring the
absorbance at 560nm using a microplate reader.
2.6. LDH Assay. Cytotoxicity was evaluated by colorimetric
assay based on the measurement of lactate dehydrogenase
(LDH) activity release from damaged cells into the super-
natant. The release of LDH is measured with a coupled
enzymatic reaction using a cytotoxicity detection kit that
results in the conversion of a tetrazolium salt into a red color
formazan. The amount of formazan formed correlated with
LDH activity. The formazan product was measured with a
microplate reader at 490nm.
2.7. TH Immunocytochemistry. Immunocytochemistry assay
was used to detect the expression of tyrosine hydroxylase
(TH) and used to estimate the number of dopaminergic
neurons in neuron cultures. After the cells were pretreated
withSHXTfor1hin24-wellplatesandfollowedbyexposureEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Eﬀects of SHXT on MPP+-induced cell death of primary mesencephalic neurons. Cells were treated with SHXT (25–75μg/mL) 1h
priortoMPP+ (100μM)additionfor48h.(a)CellviabilitywasdeterminedbyMTTassay.(b)CytotoxicitywasmeasuredbyLDHassay.Bars
represent the mean ± S.E.M. from six independent experiments. ##P<0.01, ###P<0.001 versus control (without any treatment), ∗P<0.05,
∗∗P<0.01 versus MPP+ only.
to MPP+ for 48h, cells were ﬁxed with 4% paraformaldehyde
for 30min. Then, cells were incubated in 0.2% Triton X-100
for 10min, twice wash with PBS, and incubated with 2%
BSA for 1h. The cells were then incubated with the anti-
THprimaryantibody(1:3000)overnightat4◦C.AlexaFluor
488 goat anti-rabbit IgG (H + L) was used as the secondary
antibody. Viable neurons were then enumerated under a
ﬂuorescence microscope. Six separate cultures were analyzed
foreachtreatmentandﬁverepresentativeﬁeldswerecounted
per culture.
2.8. Apoptosis Detection. Apoptotic neuronal cells were
detected by the use of double staining with Annexin
V-FITC/PI according to the manufacturer’s instructions.
Brieﬂy, cells were detached from plastic dishes and washed
twice with cold PBS. The cell pellets were suspended in
1× binding buﬀer (10mM HEPES/NaOH, pH7.4, 140mM
NaCl, 2.5mM CaCl2) at a concentration of 1 × 106 cells/mL.
Then the cells were incubated with AnnexinV-FITC and
propidium iodide (PI) for 15min (22–25◦C) in dark. The
stained cells were immediately analyzed by ﬂow cytometry
(Partec, Germany).
2.9. Determination of Reactive Oxygen Species. The level of
ROS was quantiﬁed by ﬂuorescence with H2DCF-DA. Fol-
lowing incubations with the indicated treatments, neurons
were loaded with 10μMo fH 2DCF-DA for 20min at 37◦C.
Cells were detached from plates and washed with PBS.
105 cells were analyzed by a Coulter CyFlow Cytometer
(Patrec,Germany).DCFﬂuorescencewasmeasuredusingan
excitation of 495nm and emission of 520nm.
2.10. Glutathione Quantiﬁcation. Glutathione (GSH) mea-
surement kit was purchased from Assay Designs (USA).
Neurons were grown on 12-well plates for 6 days. After
indicatedtreatment,neuronswerethencollectedandwashed
with PBS. After centrifuge, the pellets were suspended and
deproteinated in 5% metaphosphoric acid by brief soni-
cation. After centrifugation at 13,000×g for 5min, collect
the supernatants for total glutathione measurement. GSH
was determined by adding reaction Mix and GSH reductase
supplied in the kit, following incubation and measurement
by ELISA reader at 405nm for 20min at 1min interval. The
total amount of GSH was determined by means of a cali-
b r a t i o nc u r v ea n dn o r m a l i z e dt ot h ep r o t e i nc o n c e n t r a t i o n ,
which was quantiﬁed by Bio-Rad protein assay kit.
2.11. Superoxide Dismutase Activity Assay. Superoxide dis-
mutase (SOD) activity kit was purchased from Assay Designs
(USA). This method was assayed by xanthine oxidase and
conversion of WST-1 to WST-1 formazan. Neurons were
grownon12-wellplatesfor6days.Afterindicatedtreatment,
neurons were then harvested and cytosolic protein was
extracted. SOD activity was determined by adding Master
Mix and xanthine supplied in the kit, following incubation
and measurement by ELISA reader at 450nm for 10min at
1min interval. Protein concentration was quantiﬁed by Bio-
Rad protein assay kit. Then, calculate SOD activity in cell
extracts versus SOD standard curve.
2.12. Western Blotting Analysis. After indicated treatment,
neuronswerecollectedandlysedtodeterminetheexpression
of cytochrome c, caspase-9, caspase-3 and gp91phox. For the
detection of cytochrome c release, the cells were fractionated
using a mitochondria/cytosol fractionation kit according to
the manufacturer’s instruction (BioVision, USA). Protein
concentration was determined with the Bio-Rad protein
assay kit following the manufacturer’s guide. Equal amounts
of protein were separated by a polyacrylamide gel and4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀects of SHXT on MPP+-induced changes of TH staining (a)–(e) and numbers of TH-positive neurons (f) in rat primary
mesencephalic neurons. Primary mesencephalic neurons ((a), control) treated with SHXT (25–75μg/mL) 1h prior to MPP+ (100μM)
addition for 48h were further conﬁrmed by staining with anti-TH antibody (green). Numbers of TH-positive neurons were counted under
a ﬂuorescent microscope. Bars represent the mean ± S.E.M. from six independent experiments. ##P<0.01 versus control (without any
treatment), ∗P<0.05 versus MPP+ only. Scale bar = 50μm.
transferred to PVDF membranes. Nonspeciﬁc binding was
blocked with TBS-T (50mM Tris-HCl, pH 7.6, 150mM
NaCl, 0.1% Tween 20) containing 5% nonfat milk for 1h
at room temperature. The membranes were then incubated
overnight at 4◦C with one of the following speciﬁc primary
antibodies: mouse anti-cytochrome c (1:500), mouse anti-
caspase-9 (1:1000), rabbit anti-caspase-3 (1:200), mouse
anti-gp91phox (1:500) and mouse anti-β-actin (1:20000).
Membranes were washed six times 5min each with TBS-
T. The appropriate dilutions of secondary antibodies were
incubated for 1h. Following six washes with TBS-T, protein
bands were detected with ECL reagent. Protein blot images
were captured by an Imaging Densitometer with the aid
of software (Bio-ID, V.97 software for Windows 95, Vilber
Laurmat, France). Comparisons were made only between
average values of bands within the same gel.
2.13. Behavior Analysis of Locomotor Activity. Locomotor
activity was assessed in chambers (50cm × 50cm × 25cm)Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀects of SHXTon ROS level (a), gp91phox expression (b), GSH level (c), and SOD activity (d) in primary mesencephalic neurons
treated with MPP+ for 48h. Cultures were pretreated with SHXT (25–75μg/mL) for 1h before MPP+ treatment. ROS was determined by
H2DCF-DA staining. Protein expression was detected by western blotting. GSH level and SOD activity were measured by commercial kits.
Bars represent the mean ± S.E.M. from six independent experiments. Densitometry analyses are presented as the relative ratio of protein/β-
actin protein and are represented as percentages of MPP+ group. #P<0.05, ##P<0.01 versus control (without any treatment), ∗P<0.05,
∗∗P<0.01 versus MPP+ only.
connectedtoadigiscananalyzerthattransmittedthenumber
of beam breaks (activity data) to a computer. The locomotor
activity was recorded as total distance (cm) and mean
velocity (cm/s) in the 10min recording period.
2.14. TH Immunohistochemistry. TH immunohistochem-
istry has been widely used as an important method of
detecting the injury or death of dopaminergic neurons
[20, 21]. All animals were anesthetized with chloral hydrate
and the brains were perfusion ﬁxed with 4% paraformalde-
hyde. The brains were then dissected and postﬁxed in
4% paraformaldehyde overnight at 4◦C. Then, the tissues
were dehydrated and embedded in paraﬃnw a x .5 μm
thick coronal sections were then cut through the ventral
mesencephalon. Sections were stained with rabbit antibody
against TH (1:100) for 1h at room temperature. After
PBS wash, sections were incubated in simple stain mouse
MAX PO by the Universal Immunoenzyme Polymer (UIP)
methodfor30min.ThesectionswerethenincubatedinDAB
substrate for 10min and then dehydrated in graded series of
alcohol and xylene. TH-positive neurons were counted in six
sections of the sunstantia nigra region.
2.15. Statistical Analysis. Data were expressed as mean ±
S.E.M. Analysis of variance (ANOVA) was used to assess
the statistical signiﬁcance of the diﬀerences followed by
Dunnett’s test for comparison of multiple means. Probability
values (p) less than 0.05 were considered to be signiﬁcant in
all experiments. All data were analyzed with the Statistical
Package for the Social Sciences (SPSS, Chicago, IL) program
version 14.0.
3. Results
3.1. SHXT Attenuates MPP+-Induced Cytotoxicity in Rat
Primary Mesencephalic Neurons. I no r d e rt oe v a l u a t et h e
eﬀect of SHXT on MPP+-induced toxicity, mesencephalic
neurons were treated with SHXT (25–75μg/mL) 1h prior to6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: SHXT decreased numbers of apoptotic cells (a), cytochrome c release (b), cleavage of caspase-9 (c), and caspase-3 (d) in primary
mesencephalic neurons treated with MPP+(100μM) for 48h. SHXT (25–75μg/mL) were treated to neurons 1h prior to MPP+ addition.
Apoptotic cells were stained with Annexin V and PI after MPP+ exposure for 48h. Apoptosis degree of each group was shown as apoptosis
index evaluated by counting the percentage of apoptotic cells (Annexin V-positive cells) using ﬂow cytometry. Protein expression was
detected by western blotting. Densitometry analyses are presented as the relative ratio of protein/β-actin protein. Data are represented as
percentage of MPP+ group from six independent experiments. ###P<0.05 versus control (without any treatment), ∗P<0.05, ∗∗P<0.01
versus MPP+ only.
MPP+ (100μM) addition for 48h [22]. Results from MTT
test and LDH assay indicated MPP+ signiﬁcantly induced
neuronal cell death (Figures 1(a) and 1(b)). However, SHXT
showed a neuroprotective eﬀect against MPP+-induced cyto-
toxicity in rat primary mesencephalic neurons. We further
identiﬁed the eﬀect of SHXT on dopaminergic neuron phe-
notypebytyrosinehydroxylase(TH)immunocytochemistry.
Results that indicated the processes of dopaminergic neuron
in MPP+-treated cultures (Figure 2(b)) were shorter or
completely absent and the number of TH-positive neu-
rons was signiﬁcantly lower than that observed in the
control (without any treatment) (Figure 2(a)). Pretreatment
of SHXT can reduce MPP+-induced loss and death of
dopaminergic neurons (Figures 2(c)–2(f)).
3.2. SHXT Attenuates MPP+-Induced Oxidative Stress by
Decreasing ROS Production and gp91phox Activation and
Enhanced GSH Level and SOD Activity. As the oxidativeEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: SHXT increased TH-positive neurons in the substantia nigra par compacta (SNpc) of MPTP-treated mice. C57BL/6 mice were
treated with SHXT (10mg/kg or 20mg/kg, i.p.) for 7 days and then MPTP (20mg/kg, 4 times, 2h interval, i.p.) was injected on 8th day. Mice
were sacriﬁced on the 7th day after MPTP injection. (a): Control group, (b): MPTP group, (c): SHXT (10mg/kg) + MPTP, and (d): SHXT
(20mg/kg) + MPTP. Scale bar = 100μm. (e): Data represented as mean ± S.E.M. from six independent experiments. ###P<0.001 versus
control (saline only), ∗P<0.05, ∗∗P<0.01 versus MPTP group.8 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Eﬀects of SHXT on the locomotor activity in MPTP-treated mice. Locomotor activity was detected in 10min. Data of mean
velocity (a) and total movement (b) were shown as mean ± S.E.M. from six independent experiments. ##P<0.01 versus control (saline
only), ∗P<0.05, ∗∗P<0.01 versus MPTP group. (c) shows the eﬀects of SHXT on the 10-mintues track plot pictures MPTP mice. (A),
control; (B), MPTP; (C), SHXT (10mg/kg) + MPTP; (D), SHXT (20mg/kg) + MPTP.
stress is the main cause of MPP+-induced cytotoxicity,
we investigated the eﬀect of SHXT on MPP+-induced
ROS generation by measuring H2DCF-DA loaded neu-
ronal cells using ﬂow cytometry. Results indicated MPP+-
induced increase in ROS production was attenuated by
SHXT pretreatment (Figure 3(a)). Moreover, MPP+-induced
gp91phox overexpression, which plays an important role in
ROS production, was also attenuated by SHXT pretreatment
(Figure 3(b)). Furthermore, MPP+ signiﬁcantly decreased
GSH level and SOD activity in the rat primary neurons.
However, SHXT could signiﬁcantly increase GSH level
(Figure 3(c)) and SOD activity (Figure 3(d)) compared with
MPP+-treated group.
3.3. SHXT Decreased MPP+-Induced Apoptotic Signaling and
Death. As MPP+-induced neurotoxicity has been linked to
apoptosis, we assessed the eﬀect of SHXT on MPP+-induced
apoptosis of primary mesencephalic neurons by ﬂow cytom-
etry analysis using Annexin V/PI staining. Results showed
MPP+-induced apoptosis could be attenuated by SHXT
treatment (Figure 4(a)). We further evaluated the eﬀects of
MPP+-induced apoptosis-related proteins. In MPP+-treated
neurons, SHXT decreased the release of cytochrome c from
mitochondria to cytosol (Figure 4(b)) and the cleavage of
procaspase-9 and procaspase-3 (Figures 4(c) and 4(d)).
3.4. SHXT Attenuated MPTP-Induced Loss of TH-Positive
Neurons and Improved Locomotor Activity in MPTP-Treated
Mice. As shown in Figure 5,M P T Pe x p o s u r el e a d st oa
markedly loss of TH-positive neurons in the SNpc com-
pared to the control group. However, SHXT pretreatment
signiﬁcantly reduced the loss of TH-positive neurons.Evidence-Based Complementary and Alternative Medicine 9
Furthermore, in comparison with the control group, the
MPTP-treated mice displayed a signiﬁcant decrease in
locomotor activity by measuring mean velocity and total
movement distance (Figures 6(a) and 6(b)), which were
reversed by SHXT treatment. Figure 6(c) showed the eﬀects
of SHXT on the 10min track plot pictures of MPTP mice.
4. Discussion
PD is the second most prevalent age-related neurodegen-
erative diseases, primarily aﬀecting people of ages over 55
years with physiological manifestations [23]. In the present
study, we provide the evidence that the traditional Chinese
medicine SHXT possesses novel protective eﬀects in the
MPP+/MPTP models of PD. In vitro study indicates SHXT
protects dopaminergic neurons from the damage induced by
MPP+. SHXT attenuates MPP+-induced oxidative stress by
decreasing ROS production and gp91phox expression. SHXT
also enhances antioxidative defense by increasing GSH level
and SOD activity. SHXT also decreases apoptosis-related
signal and apoptotic death induced by MPP+. In vivo study
shows SHXT treatment signiﬁcantly increased TH-positive
n e u r o n si nt h eS N p ca n di m p r o v e dm o t o ra c t i v i t yi nM P T P
mice.
The antioxidant and anti-inﬂammatory eﬀects of SHXT
have been demonstrated in experimental models of various
diseases [10–14]. Oxidative damage may occur in the
parkinsonian brain and is responsible for neurodegenera-
tion. Activation of NADPH oxidase is regarded as a major
source of superoxide in a number of neurodegenerative
diseases, including PD. The neurotoxicity of MPTP was
diminished in mice lacking functional NADPH oxidase
[24]. Furthermore, antioxidant status is contributive to the
protection of MPTP-induced dopaminergic neurons loss.
For instance, MPTP depletes striatal GSH in mice, and this
eﬀect may make dopaminergic neurons more susceptible to
oxidative stress [25]. SOD is the most important enzyme for
the detoxiﬁcation of ROS and protection against oxidative
stress, and it can thus help prevent neuronal cells from
apoptosis [26]. Our previous study revealed SHXT possess
neuroprotective eﬀect against activated microglia- and 6-
OHDA-induced toxicity [14]. The present results further
showed SHXT ameliorated MPP+-induced oxidative stress
by inhibiting ROS production and gp91phox expression. It
alsoupregulatedantioxidantprotectivesystemsbyincreasing
both levels of GSH and SOD. Moreover, ROS production
contributes to the apoptotic processes found in PD [27]. The
release of cytochrome c from mitochondria to cytosol could
form apoptosome with apoptosis-activating factor (Apaf-
1) and procaspase-9, leading to the activation of caspase-
9a n dc a s p a s e - 3[ 28]. Caspase-3 has been demonstrated
to participate in MPP+-induced apoptosis and is regulated
bymitochondriadysfunction-mediatedROSoverproduction
[29]. The present results indicated that SHXT not only
attenuated MPP+-induced oxidative stress, but it also down-
regulated MPP+-induced apoptotic death and molecular
events including cytochrome c release and caspase cascade
activation.
The most debilitating symptom of PD is the loss of
motor control. The MPTP mouse model caused patho-
physiology similar to patients with PD [30]. The ability to
reﬂect behavior abnormalities of PD is one of the most
useful characteristics of this animal model. According to
our results, mice indeed display locomotor abnormalities
7 days after MPTP injection (20mg/kg, 4 times, 2h inter-
val). SHXT pretreatment improved locomotor activity in
MPTP mice. Moreover, TH is the rate-limiting enzyme in
the synthesis of catecholamine neurotransmitters such as
dopamine, epinephrine, and norepinephrine. TH activity
is progressively decreased following the loss of dopamine
neurons in the substantia nigra in the patients with PD
[20, 21]. Our results showed that SHXT signiﬁcantly reduced
the loss of TH-positive neurons not only in MPP+-treated
mesencephalic neurons in vitro but also in substantia nigra
of MPTP mice in vivo. These results suggested that SHXT
could protect dopaminergic neurons against MPTP-induced
toxicity.
In conclusion, SHXT provides novel neuroprotective
eﬀects, at least in part, via enhancing antioxidative defense,
attenuating oxidative stress and decreasing apoptotic death
in MPP+-treated mesencephalic neuron and in MPTP-
mouse model of PD. Therefore, SHXT might be a potentially
alternative and complementary medicine used in the treat-
ment of PD.
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